With 6.09 million shares changed hands, the volume of the stock remained heavier than its average volume of 67960.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.59 whereas the lowest price it dropped to was $1.42. The 52-week range on IMRN shows that it touched its highest point at $2.48 and its lowest point at $1.50 during that stretch. It currently has a 1-year price target of $4.00. Beta for the stock currently stands at 0.77.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IMRN was down-trending over the past week, with a drop of -28.10%, but this was down by -31.67% over a month. Three-month performance dropped to -6.79% while six-month performance fell -18.82%. The stock lost -11.18% in the past year, while it has lost -21.35% so far this year. A look at the trailing 12-month EPS for IMRN yields -0.58 with Next year EPS estimates of -0.01. For the next quarter, that number is -0.01. This implies an EPS growth rate of 97.54% for this year and 12.89% for next year.
Float and Shares Shorts:
At present, 5.85 million IMRN shares are outstanding with a float of 3.25 million shares on hand for trading. On 2025-10-15, short shares totaled 26157.0, which was 38.99999999999999 higher than short shares on 1757894400. In addition to Mr. Steven George Lydeamore CPA, M.B.A. as the firm’s Chief Executive Officer, Dr. Jerry Kanellos Ph.D. serves as its Chief Scientific Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. Over the past year, revenue came in at $765.19k while operating income stood at -$2.87M. EBITDA for the full year was -$3.05M.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.030052 being high and -$0.030052 being low. For IMRN, this leads to a yearly average estimate of -$0.030052.
